Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma

EP: 1.Dr. Mikhael on Treatment Selection for Early Relapse in Multiple Myeloma

Now Viewing

EP: 2.Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma

EP: 3.Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

EP: 4.Treatment Considerations in Relapsed/Refractory Multiple Myeloma

EP: 5.Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma

EP: 6.Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma

EP: 7.Dr. Martin on the Utility of CAR T-Cell Therapy in Late Relapsed Multiple Myeloma

Suzanne Lentzsch, MD, professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons of Columbia University, Columbia University Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, discusses the utility of cellular therapies in multiple myeloma.

Although definitive data are not available, established or emerging cellular therapies may be able to be adapted for patients based on age to provide the longest remissions while minimizing toxicity risk, Lentzsch explains. For example, CAR T-cell therapy will likely be the first choice for a younger patient because there may be a higher likelihood of the modality leading to prolonged remission or cure in this patient population, Lentzsch adds.

However, older patients are at an increased risk of developing CAR T-cell therapy–related toxicities, such as neurotoxicity, Lentzsch says. As such, other emerging cellular therapies, such as antibody-drug conjugates and bispecific T-cell engagers, could provide durable responses without significant toxicity in older patients with multiple myeloma, Lentzsch explains. Additional data are needed to determine whether these novel cellular therapies are also able to be used in younger patients, Lentzsch concludes.